Effect of MK0524A on Flushing Caused by Niacin (0524A-056)

Flushing Clinical Trial

Official title:
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Tolerability and Effect of MK0524A on Niacin-Induced Acute Flushing in Lipid Clinic Patients

Status Completed

Clinical Trial Summary

The primary objective of the study is to assess the effects of MK0524A in reducing flushing associated with niacin.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Flushing

Clinical Trial Details

NCT number	NCT00533611
Study type	Interventional
Source	Merck Sharp & Dohme Corp.
Contact
Status	Completed
Phase	Phase 3
Start date	April 2007
Completion date	August 2007

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03370848` - Effects of Psyllium on Niacin Tolerability	Phase 4
Completed	`NCT00930839` - Role of Prostaglandins on Niacin-Induced Flushing	N/A
Completed	`NCT03497442` - Treatment of Asian Flushing Syndrome With Topical Alpha Agonists	Early Phase 1
Completed	`NCT00895193` - Alternative Options to Minimize Niacin-Induced Flushing	N/A
Completed	`NCT00913081` - Advancing Niacin by Inhibiting Flushing (ANTI-FLUSH)	Phase 4
Completed	`NCT00536237` - MK0524A Phase IIb Study (0524A-011)(COMPLETED)	Phase 2
Completed	`NCT00533676` - Endpoint Validation Study (0524A-015)	Phase 2